-+ 0.00%
-+ 0.00%
-+ 0.00%

J&J - JNJ REPORTS RYBREVANT PLUS CHEMOTHERAPY ACHIEVES 34.3 MONTH MEDIAN OVERALL SURVIVAL IN NSCLC

Reuters·09/14/2026 12:33:38

Please log in to view news